- Pharma industry’s big bang to approach soon via microcrystalline cellulose.
- Global flexible manufacturing system for Pharmaceutical Industry forecasts 2031.
- TNXP stock prices rose by more than 370% since the start of 2023.
The Pharmaceutical giant Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.
According to a press release, the global flexible manufacturing systems for the pharmaceutical industry were valued at $1,962.2 million in 2021 and are projected to reach about thrice that value by 2031. It may register a compound annual growth rate (CAGR) of 5.3% from 2022 to 2031. This can imply that Toxin Pharmaceuticals will grow along with the pharma industry.
A flexible manufacturing system will include specialized machinery, processes and operations capable of being modified and changed within a short period to curb sudden market changes.
More opportunities await
Government and private organizations across the globe keep a watch on the healthcare industry as it is closely knitted to the lives of people and animals. Also, it’s one of the few industries that is highly affected by politics. Furthermore, diseases adapt and often become immune to the existing medicines. All these factors propose an ongoing cycle of research and development in the healthcare industry.
As mentioned in the reports, the global microcrystalline cellulose market is anticipated to witness dramatic growth in the forecast period of 2024-2028. This can be allocated to the growing demand for the resource from various end-user industries, including pharmaceuticals. Microcrystalline cellulose is a generally used bulking-agents in the pharmaceutical industry, which is expanding globally due to ongoing pandemic-like situations.
The projection extends an opportunity to the company, which already has a niche in the central nervous system and infectious diseases, inclusive of the vaccines to prevent COVID-19 and related treatments. Another field where the company can expand is using the Internet of Things (IoT) in healthcare.
IoT healthcare proposes using digital healthcare applications that aim to transform, mechanize and evolve the whole healthcare system. The global internet of medical things (IoMT) market is expected to reach $187.60 billion by 2028, which can be a stream to discover with the evolving industry.
TNXP Stock Price Analysis
The stock prices were under consolidation for a long period, before rising, by more than 370%. The rally faced strong sellers, pushing it down by about 38%, to $1.04, at press time. The volume recorded a blend of buyers and sellers, which became active after stagnating for a long. The consolidating period tested the support zone of $0.65 to $0.29 several times.
The RSI descends from the overbought zone to the 60-70 range to display a downtick in prices. The MACD records ascending buyer bars as the lines undergo a bullish divergence. With a negative 0.53 P/E Ratio, the company stands undervalued but can lure holders as its EPS is valued at $56.81%, which is 1000% of what the industry holds.
The pharma industry is extended with a basket filled with areas to strive and expand. Tonix Pharmaceutical is capable of achieving untapable advantages by deploying all available resources. The TNXP holders can watch the support zone near $0.29 to buy the dip.
Support levels: $0.29 and $0.10
Resistance levels: $1.70 and $2.20
The views and opinions stated by the author, or any people named in this article, are for informational purposes only, and they do not establish financial, investment, or other advice. Investing in or trading crypto assets comes with a risk of financial loss.
Steve Anderson is an Australian crypto enthusiast. He is a specialist in management and trading for over 5 years. Steve has worked as a crypto trader, he loves learning about decentralisation, understanding the true potential of the blockchain.